CEO David Bearss to Share Insights on Obesity Treatments
Halia Therapeutics, Inc., a leading biopharmaceutical firm focused on creating progressive treatments for chronic inflammatory diseases, has announced that their Co-Founder, President, and CEO, David J. Bearss, Ph.D., will present novel findings regarding oral obesity therapeutics. This presentation will take place at the upcoming Obesity Innovation Therapeutics Summit. The summit is set to gather experts and thought leaders from various fields to exchange the latest developments in obesity treatment solutions.
Event Details and Presentation Highlights
During this insightful summit, Dr. Bearss will engage in discussing breakthrough advancements addressing obesity. His focus will be on the need for more patient-centric approaches in developing medications that can replace the often unwieldy injectable therapeutics with effective oral alternatives. The summit emphasizes recent innovations, mechanisms of action, and the potential of combination therapies.
Presentation Information
Title: Patient-Centric Development: Exploring Oral Obesity Therapeutics to Move Away from Injectable Peptides
Date: December 11, 2024
Time: 5 p.m. PT
Presenter: David J. Bearss, Ph.D., Co-Founder & CEO, Halia Therapeutics
Panel Discussion Overview
In addition to his presentation, Dr. Bearss will be an integral part of a panel discussion focusing on the various supply chain challenges that confront the obesity therapeutics domain. This conversation will allow the presentation of diverse perspectives from several leaders in the field.
Key Panelist Information
Title: The Obesity Race on the Manufacturing Floor – Exploring Supply Challenges with Innovations in Discovery
Date: December 11, 2024
Time: 2:40 p.m. PT
Panelists:
- David J. Bearss, Ph.D., Co-Founder & CEO, Halia Therapeutics
- Feng Liu, Executive Director, Research & Development, Regor Pharmaceuticals
- Adam Mendelsohn, Chief Executive Officer, Vivani Medical
About Halia Therapeutics, Inc.
Halia Therapeutics is significantly changing the treatment landscape for chronic inflammatory and neurodegenerative diseases, boasting a robust pipeline featuring groundbreaking therapeutics. Their projects aim to target NEK7 and LRRK2, which are recognized as critical contributors to inflammation and cellular dysfunction. Halia's lead candidate, HT-6184, an innovative NEK7/NLRP3 inhibitor, has shown promise in early Phase I trials, focusing on safety and tolerability through oral dosing regimens. This candidate is currently under investigation in two Phase II studies - one studying its efficacy for lower-risk myelodysplastic syndromes (LR-MDS) and another exploring its role in managing postoperative inflammation and pain.
Recently, Halia has kicked off a Phase I trial for HT-4253, a pioneering LRRK2 inhibitor aimed at treating neurodegenerative conditions. These studies underscore Halia's commitment to advancing science-driven solutions to improve patient outcomes.
Halia’s Mission and Vision
With its headquarters based in Utah, Halia Therapeutics is diligently dedicated to enhancing patient care through scientifically backed innovations in treatment methodologies. Their efforts are grounded in addressing the needs of individuals facing chronic health conditions, aiming to provide effective and convenient medication options for diverse patient populations.
Frequently Asked Questions
What will David Bearss present at the summit?
Dr. Bearss will discuss innovative research on oral obesity therapeutics and the shift away from injectables.
When is the Obesity Innovation Therapeutics Summit?
The summit will take place from December 10-12, 2024.
What challenges will be addressed in the panel discussion?
The panel will cover supply chain challenges in the obesity therapeutics landscape.
How is Halia Therapeutics advancing treatment options?
Halia is developing novel treatments targeting NEK7 and LRRK2, aiming to improve therapeutic efficacy and delivery.
Where can I find more information about Halia Therapeutics?
More information can be found on Halia's official website.
